This conference already took place.

We would like to thank all delegates, speakers and cooperation partners for this successful event!
For further information on our other conferences and further topics please visit our WEBSITE .


Highlight Speakers:

Successful strategies to incorporate regulations and employ the most promising DMPK tools

Fachtagung für Experten aus dem Bereich Drug Transporters der Pharmaindustrie. Die Konferenz diskutiert die Anforderungen an Drug Transporter hinsichtlich neuer regulatorischer Vorgaben und des möglichen Einflusses von genetischem Polymorphismus. Die Konferenz wird auf Englisch abgehalten. .

Drug transporters exert a vital influence on drug absorption, disposition, metabolism and elimination and are seen as an essential part of predicting drug disposition. However, identifying and employing the right membrane transporters remains a challenge as does the interpretation and translation of transport data. In addition, the forthcoming regulatory guidelines of the American FDA along with the inputs of EMA and the ITC will help clarify which drug transporters are relevant. In order to better understand and correctly implement all requirements there is still a real need to accelerate the harmonization of regulatory requirements.

Focus on PK/PD, ADME, DMPK, BBB and PBPK

Experts from international companies such as Sanofi-Aventis, GSK, Bayer and Novartis will report on first-hand experiences and best practices.

  • Learn how to strategically apply regulatory requirements by understanding the differences between regulatory agencies
  • Discover what impact drug transporters exert on DDI by better analysing in vivo alteration in drugs PK
  • Utilise PBPK-modelling techniques to increase prediction of DT function and expression by successfully creating virtual organs
  • Discover how pharmacogenomics may affect drug design by understanding the impact of genetic polymorphism on DT
  • Apply the best in vitro and in vivo methods to better assess drug penetration at the BBB by strategically optimizing early discovery compounds

Following companies will present at the conference:

    • Sanofi-Aventis GmbH, Germany
    • GlaxoSmithKline PLC, UK
    • University of Toronto/Ministry of Health of Ontario, Canada
    • Abbott GmbH & Co. KG, Germany
    • Laboratoires Fournier/Abbott Laboratories, France
    • European Medicine Agency (EMA), UK
    • University of Helsinki, Finland
    • University of Manchester, UK
  • H.Lundbeck AS, Denmark
  • Tohoku University, Japan
  • University of Greifswald, Germany
  • International Transporter Consortium ITC
  • Addex Pharmaceuticals, Switzerland
  • Novartis Institutes for BioMedical Research, USA
  • Bayer Pharma AG, Germany

Interactive Workshop Day | 27 February 2012

  • Workshop B: Predicting transporter-mediated DDI: Static and PBPK modelling approaches
  • Workshop D: Drug and nutrient transport across biological barriers: Potential therapeutic applications and/or toxicological consequences

Testimonials

“I felt that the conference gave cutting edge information in the area of transporter understanding.”
James Clarke, Principle Scientist, GlaxoSmithKline PLC
Sponsors Media Partners
sponsors _media

[ Register Now ]